Spero Therapeutics, Inc.: 10-Q filed 2025-11-13
What Spero Therapeutics, Inc. reported in its quarterly report filed 2025-11-13 (fiscal Q3 2025): 31 published measures, 98 facts as tagged in accession 0001193125-25-280174.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-11-13
- Fiscal period
- fiscal Q3 2025
- Accession
- 0001193125-25-280174 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Spero Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 54,170,000 | USD | |
| At 2024-12-31 | 110,543,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 27,676,000 | USD | |
| At 2024-12-31 | 64,420,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 26,494,000 | USD | |
| At 2025-06-30 | 32,828,000 | USD | |
| At 2024-12-31 | 46,123,000 | USD | |
| At 2024-09-30 | 65,507,000 | USD | |
| At 2024-06-30 | 80,500,000 | USD | |
| At 2023-12-31 | 106,894,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 48,616,000 | USD | |
| At 2024-12-31 | 52,889,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -7,382,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -22,948,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -17,147,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -47,678,000 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -4,273,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -43,000 | USD | 274 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 5,442,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 25,505,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 13,469,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 32,933,000 | USD | 274 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 0 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 12,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 65,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 319,000 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | -482,586,000 | USD | |
| At 2024-12-31 | -459,638,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 56,280,844 | shares | 92 |
| 2025-01-01 to 2025-09-30 | 55,866,392 | shares | 273 |
| 2024-07-01 to 2024-09-30 | 54,124,862 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 53,869,824 | shares | 274 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 56,280,844 | shares | 92 |
| 2025-01-01 to 2025-09-30 | 55,866,392 | shares | 273 |
| 2024-07-01 to 2024-09-30 | 54,124,862 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 53,869,824 | shares | 274 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -0.13 | USD/shares | 92 |
| 2025-01-01 to 2025-09-30 | -0.41 | USD/shares | 273 |
| 2024-07-01 to 2024-09-30 | -0.32 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | -0.89 | USD/shares | 274 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -0.13 | USD/shares | 92 |
| 2025-01-01 to 2025-09-30 | -0.41 | USD/shares | 273 |
| 2024-07-01 to 2024-09-30 | -0.32 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | -0.89 | USD/shares | 274 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 0 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 0 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 290,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 290,000 | USD | 274 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 1,048,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 3,318,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 2,154,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 6,290,000 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -7,916,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -25,091,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -18,593,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -51,636,000 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 52,323,000 | USD | |
| At 2024-12-31 | 107,276,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 13,649,000 | USD | |
| At 2024-12-31 | 49,074,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 1,395,000 | USD | |
| At 2024-12-31 | 7,306,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 13,358,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 50,596,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 32,062,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 84,569,000 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 8,597,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 32,875,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 26,864,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 67,921,000 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 56,311,795 | shares | |
| At 2024-12-31 | 54,593,527 | shares |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 1,694,000 | USD | |
| At 2024-12-31 | 3,114,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 153,000 | USD | |
| At 2024-12-31 | 153,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 1,248,000 | USD | |
| At 2024-12-31 | 1,911,000 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -7,382,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -22,948,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -17,147,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -47,678,000 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 4,174,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 16,876,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 5,198,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 16,648,000 | USD | 274 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 0 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 2,000 | USD | 274 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 2,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 7,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -26,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -39,000 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 534,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 2,143,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 1,156,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 3,668,000 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -5,911,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 4,712,000 | USD | 274 |
Inspect the source
- Entity
- Spero Therapeutics, Inc. / CIK 0001701108
- Captured
- 2026-09-21T17:23:59.573Z
- SEC response SHA-256
7d8d28a786cc1f9d14a78b641809cfb8611771dec1312fb75a17633e4e3e7a24
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001701108.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))